Skip to main content
See every side of every news story
Published • loading... • Updated

Pebrilzo Wins FDA Approval as a Second Perjeta Biosimilar—but U.S. Patients May Have to Wait Until Late 2028

The biosimilar expands Biocon’s oncology portfolio and offers a new treatment option for patients with HER2-positive breast cancer.

Summary by Medical Daily
The FDA approved Biocon's Pebrilzo, a second Perjeta biosimilar for adults with HER2-positive breast cancer. It will not launch in the United States before the third quarter of 2028.

5 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Express Pharma broke the news on Monday, November 16, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal